MedTrace Logo

Assessing Diagnostics At Point-of-care for Tuberculosis

NCT05941052 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1350

Last updated 2026-03-09

No results posted yet for this study

Summary

Every year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide. The Assessing Diagnostics At Point-of-care for Tuberculosis (ADAPT) study seeks to reduce the burden of TB worldwide by evaluating faster, simpler, and less expensive TB triage and diagnostic tests.

Conditions

Interventions

DIAGNOSTIC_TEST

Tongue swab-based molecular assays

The investigators will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.

Sponsors & Collaborators

  • University Hospital Heidelberg

    collaborator OTHER

  • KNCV Tuberculosis Foundation

    collaborator OTHER

  • Bingham University

    collaborator UNKNOWN

  • University of California, Irvine

    collaborator OTHER

  • De La Salle University Medical Center

    collaborator OTHER

  • Centre for Infectious Disease Research in Zambia

    collaborator OTHER

  • Johns Hopkins University

    collaborator OTHER

  • University of California, San Francisco

    lead OTHER

Principal Investigators

  • Adithya Cattamanchi · University of California, Irvine

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-28
Primary Completion
2028-09-30
Completion
2028-09-30
FDA Device
Yes

Countries

  • Nigeria
  • Philippines
  • Zambia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05941052 on ClinicalTrials.gov